A Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors

Summary

This is a study designed to assess the safety of administration of up to 3 dose levels of eritoran in subjects undergoing or scheduled to undergo allogeneic bone marrow transplant (BMT). An allogeneic BMT is the transplantation of blood stem cells taken from the bone marrow or blood of another person.

Timeline

Start

2008-09

Primary completion

2008-11

Completion

—

Outcome

Outcome not reported

Stopped (Business): “This study was terminated in November 2008 due to "a business decision (resources)".”

Drugs

Indications